Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 31Genitourinary 22Thoracic 20Gastrointestinal 11Sarcoma 10Gynecologic 8CNS 7Head & Neck 6Other solid neoplasm 3Dermatologic 2Tumor-Agnostic 1Endocrine 1

Conditions

Pituitary Neoplasms 1Neurilemmoma 1Nerve Sheath Neoplasms 1Meningioma 1Brain Neoplasms 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Radiation Dose Hypofractionation × Endocrine × Clear all
NCT04278118 2026-02-17

HiPPI

Emory University

Phase NA Recruiting
70 enrolled
CNSEndocrine

Brain Neoplasms, Meningioma, Neurilemmoma, Pituitary Neoplasms, Nerve Sheath Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡